Volume: 43 Issue: Supplementary 1
Year: 2023, Page: 221-224, Doi: https://doi.org/10.51248/.v43i1.2424
Introduction and Aim: Toll-like receptors (TLRs) are cell innate immune receptors that explore microbial molecules. A quantity of single-nucleotide polymorphisms (SNPs) within the TLR genes have been related with altered susceptibility to infectious, inflammatory, and allergic diseases suggesting: This study was conducted to investigate the relationship between genetic polymorphism in TLR4 gene (rs1927911) with susceptibility to UTIs in a sample of Iraqi patients.
Materials and Methods: Blood samples were collected from 220 patients who had UTIs and 69 healthy subjects as control group, during the period from October 2021 to March 2022, at the Rheumatology Department of Clinic Consultant at Al-Yarmouk Hospital. The genetic study included an extraction of genomic DNA and PCR technique, to detect the role of TLR4 gene in the variation site (rs1927911) as a risk factor for the incidence of UTIs.
Results: The results of genotype distribution and allele frequency of rs1927911 indicated, CC (18.6 %), CT (70 %) and TT (11.4 %) among the patients while 57.9 % for CC and 26.1%; 16% for CT, TT genotypes respectively of healthy control. Heterozygous (CT) may be considered as a risk factor among UTIs patients. The results revealed significant differences between UTIs patients and healthy controls in serum levels TLR4, IL-6 IL-2, TNF-α and IL-10 at P ≤ 0.005. In addition, the data found a highly significant difference of serum level of TLR4 protein with patients who have a carrier CT genotype.
Conclusion: our findings indicated that the carriers of CT genotype of TLR4 (rs1927911) were significantly more prone to UTIs.
Keywords: UTIs; LPS; gene polymorphism; TLR4 gene.
1. Nicolle, L., Gupta, K., Bradley, S. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the infectious Diseases Society of America. Clin Infect Dis. 2019; 68(10): e83-110.
2. Wagenlehner, F., Bjerklund Johansen, T., Cai, T., Koves, B., Kranz, J., et al., Epidemiology, definition, and treatment of complicated urinary tract infections. Nature Reviews Urology. 2020; 17(10): 586-600.
3. AlChalabi, R., Al–Ubaidy, A., Al-Ibadi, M. Detection of urovirulence genes (eae, E-hly, α-hly) of uropathogenic Escherichia coli by specific PCR. Journal of Biotechnology Research Center. 2010, 4(1): 44-54.
4. Tang, M., Quanstrom, K., Jin, C., Suskind, A. Recurrent urinary tract infections are associated with frailty in older adults. Urology. 2019; 123:24-27.
5. Mariano, L.L., Ingersoll, M. The immune response to infection in the bladder. Nat. Rev. Urol. 2020; 17: 439-458.
6. Ambite, I., Butler, D., Murphy, L., Wan, Y. Rosenblad, T., Tran, T. H., et al., Molecular determinants of disease severity in urinary tract infection. Nature Reviews Urology. 2021; 18:468-486.
7. Saleh, T., Hashim, S., Malik, S.N., AL-Rubaii, B.A.L. The impact of some of the nutrients on swarming phenomenon and detection of the responsible gene RsbA in clinical isolates of Proteus mirabilis. International Journal of Research in Pharmaceutical Sciences. 2020; 11(1):437-444.
8. Abdul-Gani, M.N., Laftaah, B.A. Purification and characterization of chondroitinase ABC from Proteus vulgaris, an Iraqi clinically isolated. Current Science. 2017:2134-2140.
9. Kadhim AL-Imam, M.J., AL-Rubaii, B.A. The influence of some amino acids, vitamins and anti-inflammatory drugs on activity of chondroitinase produced by Proteus vulgaris caused urinary tract infection. Iraqi Journal of Science. 2016; 57 (4A): 2412-2421.
10. Bustos, V., Escrig, A., López, C., Estellés, R., Jerusalem, K., Navalón, C.M., et al., Prospective cohort study on
hospitalized patients with suspected urinary tract infection and risk factors for multidrug resistance. Scientific Report. 2021; 11(11927):1-8.
11. Saleh, T.H., Hashim, S.T., Malik, S.N., AL-Rubaii, B.A.L. Down-regulation of fliL gene expression by Ag nanoparticles and TiO2 nanoparticles in pragmatic clinical isolates of Proteus mirabilis and Proteus vulgaris from urinary tract infection. Nano Biomedicine and Engineering. 2019; 11(4):321-332.
12. Garcia-Culebras, A., Duran-Laforet, V., Pena-Martinez, C., Moraga, A., Ballesteros, I., Cuartero, M., et al., Role of TLR4 (toll-like receptor 4) in N1/N2 neutrophil programming after stroke. Stroke. 2019; 50(10): 2922-2932.
13. Ciesielska, A., Matyjek, M., Kwiatkowska, K. TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling. Cell Mol Life Sci. 2021;78(4):1233-1261.
14. Mazgaeen, L., Gurung, P. Recent advances in lipopolysaccharide recognition systems. Int J Mol Sci. 2020; 21(2):379.
15. Xu, J. J., Liu, K.Q., Ying, Z. M., Zhu, X.W., Xu, X.J., Xue-Jin, X., Zhao, P.P., et al., Effect of CD14 polymorphisms on the risk of cardiovascular disease: evidence from a meta-analysis. Lipids in Health and Disease .2019;18(74):1-14.
16. Huang, W., Xu, Y., Wan, S. Association of Toll-like 4 receptor gene polymorphisms (rs4986790, rs4986791) with the risk of urinary tract infection: A systematic review and meta-analysis. The Kaohsiung Journal of Medical Sciences. 2020; 36(3):206-211.
17. Shehab, Z.H. and Laftah, B.A. Correlation of nan1 (Neuraminidase) and production of some type III secretion system in clinical isolates of Pseudomonas aeruginosa. Bioscience Research. 2018; 15(3): 1729-1738.
18. Abdulrazaq, R.A., Mahmood, W.S., Alwan, B., Saleh, T.H., Hashim, S.T., Al-Rubaii, B.A.L. Biological Study of protease produced by clinical isolates of Staphylococcus aureus. Research Journal of Pharmacy and Technology.2022; 15(12):5415-5420.
19. Rasoul, L.M., Marhoon, A.A., Albaayit, S.F.A., Ali, R.W., Saleh, T.H., Al-Rubaii, B.A.L. Cytotoxic effect of cloned EGFP gene on NCI-H727 cell line via genetically engineered gene transfer system. Biomedicine. 2022; 42(5):938-942.
20. Noreen, M., Shah, M., Mall, S., Choudhary, S., Hussain, T., Reza, I. TLR4 polymorphisms and disease susceptibility. Inflamm Res. 2012; 61(3):177-188.
21. Pandey, N., Chauhan, A. Jain, N. TLR4 polymorphisms and expression in solid cancers. Molecular Diagnosis and Therapy. 2018; 22:683-702
22. Karananou, P., Tramma, D., Katafigiotis, S., Alataki, A., Lambropoulos, A., Papadopoulou-Alataki, E. The role of TLR4 Asp299Gly and TLR4 Thr399Ile polymorphisms in the pathogenesis of urinary tract infections: first evaluation in infants and children of Greek origin. Journal of Immunology Research. 2019; 2019:6503832.
23. Lau, M., Dharmage, S., Burgess, J., Win, A., Lowe, A., Lodge, C., et al., The interaction between farming/ rural environment and TLR2, TLR4, TLR6 and CD14 genetic polymorphisms in relation to early and late-onset asthma. Science Report. 2017; 7(43681).
24. Abdalhussin, H., Jafar, N., Alrifai, S. Assessment of TLR2 & TLR4 in urine of bacteria isolated from urinary tract infection of Baghdad hospitals. HIV Nursing. 2022; 22(2):3444-3448.
25. Dinarello, C. Overview of the IL1 family in innate inflammation and acquired immunity. Immunological reviews. 2018; 281(1): 8-27.
26. Butler, D., Ambite, I., Wan, M., Tran, T., Wullt, B., Svanborg, C. Immunomodulation therapy offers new molecular strategies to treat UTI. Nat Rev Urol. 2022;19(7):419-437.
Risala H. Allami, Muhanad Najm Abdullah, Basma K. Al-Ani, Rawaa AlChalabi, Sawsan S. Hamzah. Study of the association of toll like-4 receptor gene polymorphism (rs1927911) and susceptibility to urinary tract infection among Iraqi patients. Biomedicine: 2023; 43(1) Supplementary issue: 221-224